Literature DB >> 16710305

Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations.

S Giuntoli, E Rovida, V Barbetti, M G Cipolleschi, M Olivotto, P Dello Sbarba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16710305     DOI： 10.1038/sj.leu.2404224

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  33 in total

1.  Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.

Authors:  Serena Giuntoli; Michele Tanturli; Federico Di Gesualdo; Valentina Barbetti; Elisabetta Rovida; Persio Dello Sbarba
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

2.  Very low oxygen concentration (0.1%) reveals two FDCP-Mix cell subpopulations that differ by their cell cycling, differentiation and p27KIP1 expression.

Authors:  A V Guitart; C Debeissat; F Hermitte; A Villacreces; Z Ivanovic; H Boeuf; V Praloran
Journal:  Cell Death Differ       Date:  2010-07-30       Impact factor: 15.828

3.  Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells.

Authors:  E Del Poggetto; M Tanturli; N Ben-Califa; A Gozzini; I Tusa; G Cheloni; I Marzi; M G Cipolleschi; Y Kashman; D Neumann; E Rovida; P Dello Sbarba
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

4.  Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Authors:  Artur Slupianek; Yashodhara Dasgupta; Shu-Yue Ren; Ewa Gurdek; Milene Donlin; Margaret Nieborowska-Skorska; Fabrice Fleury; Tomasz Skorski
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

Review 5.  Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

Authors:  Danilo Perrotti; Giovannino Silvestri; Lorenzo Stramucci; Justine Yu; Rossana Trotta
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 6.  Why doesn't imatinib cure chronic myeloid leukemia?

Authors:  Robert L Redner
Journal:  Oncologist       Date:  2010-02-02

7.  Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.

Authors:  F Zhao; A Mancuso; T V Bui; X Tong; J J Gruber; C R Swider; P V Sanchez; J J Lum; N Sayed; J V Melo; A E Perl; M Carroll; S W Tuttle; C B Thompson
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

8.  TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.

Authors:  Prahlad V Raninga; Giovanna Di Trapani; Slavica Vuckovic; Kathryn F Tonissen
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

9.  Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.

Authors:  Giulia Cheloni; Michele Tanturli; Ignazia Tusa; Ngoc Ho DeSouza; Yi Shan; Antonella Gozzini; Fréderic Mazurier; Elisabetta Rovida; Shaoguang Li; Persio Dello Sbarba
Journal:  Blood       Date:  2017-06-02       Impact factor: 22.113

10.  AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia.

Authors:  V Barbetti; I Tusa; M G Cipolleschi; E Rovida; P Dello Sbarba
Journal:  Cell Death Dis       Date:  2013-03-14       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.